AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12393113
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 4.3 microg.kg(‐1) plus IV buprenorphine 1.3 microg.kg(‐1) (Group 3)
Trial: 10207203
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of basic fibroblast growth factor (bFGF) within hours after the onset of ischemia
Trial: 10207203
Drug: Intracisternal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracisternal administration of basic fibroblast growth factor (bFGF) starting at one day after ischemia
Trial: 10207203
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of basic fibroblast growth factor (bFGF) as a recovery-promoting agent in subacute stroke
Trial: 2645756
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg once daily
Trial: 7553405
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg daily (one-year open treatment)
Trial: 373489
Drug: Methazolamide (Neptazane)
RxNorm normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methazolamide (Neptazane) 50 mg p.o.
Trial: 373489
Drug: Methazolamide (Neptazane)
RxNorm normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methazolamide (Neptazane) 100 mg p.o.
Trial: 31146741
Drug: NS-21 cream
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-21 cream applied three times per day during RT or CCRT
Trial: 31146741
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment applied three times per day during RT or CCRT
Trial: 31146741
Drug: NS-21 cream
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-21 cream
Trial: 27241125
Drug: Subcutaneous Adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Adipose Tissue (SAT)
Trial: 24935272
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) at a dose of 5 μg/kg subcutaneously every 12 hours for 5 consecutive days (group A)
Trial: 24935272
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) plus G-CSF (group A)
Trial: 24935272
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) alone (group B)
Trial: 20849244
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (target 13.0-15.0 g/dL; Group 1)
Trial: 20849244
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (target 10.5-11.5 g/dL; Group 2)
Trial: 16716541
Drug: Swaddled babies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swaddled babies kept in the nursery with breast-milk supplements
Trial: 16716541
Drug: Swaddled babies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swaddled babies receiving supplements
Trial: 16224157
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil monotherapy
Trial: 16224157
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ongoing lamivudine
Trial: 9483448
Drug: Cimetidine 50
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 50 mg/kg administered intravenously just prior to IHCP (cimetidine group)
Trial: 710028
Drug: Naproxen alone
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen alone (500 mg single oral dose)
Trial: 710028
Drug: Naproxen with
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen with probenecid (500 mg 4 times a day)
Trial: 710028
Drug: Naproxen with
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen with probenecid (250 mg twice daily for 8 days)
Trial: 31707266
Drug: Recommended Usual
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended Usual Care (R‐UC): 8 weeks of nicotine patch plus brief counseling
Trial: 31707266
Drug: Abstinence‐Optimized Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence‐Optimized Treatment (A‐OT): 3 weeks of pre‐quit mini‐lozenges, 26 weeks of nicotine patch plus mini‐lozenges, 11 counseling contacts, and 7‐11 automated reminders
Trial: 24158333
Drug: Standard implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implant (4-mm platform)
Trial: 9048709
Drug: Mitoxantrone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (20 mg IV monthly) and methylprednisolone (1 g IV monthly)
Trial: 3525022
Drug: Oral terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline, 5 mg qid
Trial: 3525022
Drug: Inhaled terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline, 400 micrograms qid
Trial: 3525022
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablets or metered-dose inhalers)
Trial: 31286733
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment and care (Control group)
Trial: 28190788
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg kg−1 hour−1
Trial: 28190788
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg kg−1 hour−1
Trial: 21502549
Drug: Nadroparin (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (subcutaneous administration for 6 weeks: 2 weeks at therapeutic dose, 4 weeks at half therapeutic dose)
Trial: 15575830
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol (0.5%) without lacrimal occlusion
Trial: 9072665
Drug: Immunomodulating drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulating drug of bacterial derivation
Trial: 1476466
Drug: Quinine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine infusion regimen (8 mg of quinine base/kg of body weight over 1 h followed by 8 mg of base/kg over 7 h, then 8 mg/kg over 8 h 3 times daily for 3 days)
Trial: 1476466
Drug: Classical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical regimen (8 mg of base/kg over 8 h, 3 times daily for 3 days)
Trial: 6439759
Drug: Oral digoxin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral digoxin, 0.5 mg daily, on days 10 through 22 of a menstrual cycle
Trial: 6439759
Drug: Intravenous digoxin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous digoxin, 0.5 mg daily for days 7 through 21 of a menstrual cycle
Trial: 30820517
Drug: Creatine-High (CR-H;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine-High (CR-H; 0.3 g/kg/day of creatine + 0.1 g/kg/day of maltodextrin)
Trial: 30820517
Drug: Creatine-Moderate (CR-M;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine-Moderate (CR-M; 0.1 g/kg/day of creatine + 0.3 g/kg/day of maltodextrin)
Trial: 30820517
Drug: Placebo (PLA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA; 0.4 g/kg/day of maltodextrin)
Trial: 3105472
Drug: verapamil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (5 mg)
Trial: 29898437
Drug: heparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin (5,000 IU)
Trial: 20130407
Drug: Specific diet
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific diet based on IgG antibodies against food antigens
Trial: 17919542
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine patch applied for 3 days
Trial: 17919542
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine patch applied for 4 days
Trial: 8527287
Drug: Tolcapone (10-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (10-800 mg)
Trial: 6230173
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg bid for 14 days)
Trial: 30835822
Drug: Intra-operative dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative dexmedetomidine (0.5 µg.kg-1 bolus followed by 0.4 µg.kg-1.hr-1 infusion)
Trial: 30701937
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (omeprazole, amoxicillin, clarithromycin)
Trial: 30701937
Drug: Four-component therapy
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-component therapy with bismuth (omeprazole, tetracycline, metronidazole, bismuth tricalium dicitrate)
Trial: 30701937
Drug: Hybrid scheme
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid scheme (first 5 days: omeprazole and amoxicillin, next 5 days: omeprazole, amoxicillin, clarithromycin, metronidazole)
Trial: 19230758
Drug: Auto-CPAP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-CPAP titration (optimal pressure 7.0 cmH2O)
Trial: 27134145
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment (esomeprazole 40mg, amoxicillin 1g/bid for 5 days, followed by 5 days of esomeprazole 40mg, clarithromycin 500mg and metronidazole 500mg bid for 10 days)
Trial: 27134145
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (same drugs as concomitant but taken sequentially)
Trial: 10078856
Drug: 2% aminophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% aminophylline cream (AC)
Trial: 10078856
Drug: no cream
RxNorm normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no cream (NC)
Trial: 10078856
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream (PC)
Trial: 28335664
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy intervention (CBTi)
Trial: 21832111
Drug: Combined (Clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (Clomiphene citrate + Metformin)
Trial: 11715169
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (0.5 mL containing A/Wuhan/359/95 (H3N2), A/Texas/36/91 (H1N1), B/Beijing/184/93)
Trial: 9570259
Drug: 15 or
RxNorm normalized name: Oseni 25/15 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 or 30 mg lansoprazole/day
Trial: 9570259
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole/day
Trial: 8056998
Drug: lorazepam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam 0.75 mg
Trial: 8056998
Drug: lorazepam up
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lorazepam up to 1.5 mg
Trial: 3383875
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg b.i.d. (n = 154)
Trial: 31127676
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.8 mg daily for 3 months
Trial: 28715540
Drug: Pyridoxine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (200 mg daily for a maximum of 8 cycles of capecitabine)
Trial: 28715540
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for a maximum of 8 cycles of capecitabine)
Trial: 20185003
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine response (10 microg/kg/min)
Trial: 18388122
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate (CC) 500 mg
Trial: 18388122
Drug: Sevelamer Hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer Hydrochloride (SEV) 800 mg
Trial: 15898218
Drug: Automated system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated system with recommendation to prescribe angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers
Trial: 12534414
Drug: Alosetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (1 mg b.d.)
Trial: 10368502
Drug: Prepidil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepidil (0.5 mg intracervically every 6 hours)
Trial: 1702812
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/day for 3 days)
Trial: 6276584
Drug: β-endorphin 2
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-endorphin 2 mg intrathecally
Trial: 6276584
Drug: morphine HCl
RxNorm normalized name: morphine HCl
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine HCl 0.2 mg intrathecally
Trial: 31449470
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by standard chemoradiation (CRT)
Trial: 23715821
Drug: Sertaconazole 2
RxNorm normalized name: sertaconazole 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole 2 % cream
Trial: 23715821
Drug: Pimecrolimus 1
RxNorm normalized name: pimecrolimus 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1 % cream
Trial: 16923461
Drug: Clopidogrel 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 900 mg loading dose
Trial: 11521332
Drug: Acetylsalicylic acid,
RxNorm normalized name: Acetylsalicylic Acid, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid, lipid-lowering drugs, vitamins, and exercise (primary preventive effects)
Trial: 31751758
Drug: Antihistamine therapy
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine therapy
Trial: 31751758
Drug: Cyclospirine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclospirine therapy
Trial: 28941141
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of ortho-silicic acid stabilized by hydrolyzed collagen (group 1)
Trial: 22944873
Drug: Early integrated
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early integrated treatment group (ART within 4 weeks of tuberculosis treatment initiation)
Trial: 22944873
Drug: Late integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late integrated treatment group (ART within 4 weeks of completion of the intensive phase of tuberculosis treatment)
Trial: 22944873
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment group (ART within 4 weeks after tuberculosis therapy completion)
Trial: 20090313
Drug: Pullulan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pullulan (12 g/day)
Trial: 20090313
Drug: Promitor Resistant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promitor Resistant Starch (12 g/day)
Trial: 20090313
Drug: Soluble fiber
RxNorm normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble fiber dextrin (12 g/day)
Trial: 20090313
Drug: Promitor Soluble
RxNorm normalized name: Domitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promitor Soluble Corn Fiber (12 g/day)
Trial: 20090313
Drug: All fibers
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All fibers (12 g/day)
Trial: 17255841
Drug: Low osmolarity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low osmolarity WHO-ORS (G-ORS) and rice-based ORS (R-ORS) combined as control
Trial: 15377472
Drug: CHOP +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP + G-CSF
Trial: 9590570
Drug: Captopril (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-100 mg daily)
Trial: 9590570
Drug: Atenolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50-100 mg daily)
Trial: 3281774
Drug: Codeine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (120 mg)
Trial: 31339789
Drug: Quadrivalent influenza
RxNorm normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent influenza vaccine (QIV) information and education
Trial: 31339789
Drug: Concern that
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concern that vaccines need to be carefully administered
Trial: 31339789
Drug: Mistrust of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistrust of new vaccines
Trial: 30213012
Drug: High-dose IFNα‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFNα‐2b (9 million IU)
Trial: 30213012
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose IFNα‐2b and red light therapy
Trial: 30213012
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant IFNα‐2b (1 million IU)
Trial: 24656288
Drug: Sitaxentan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxentan 50 mg
Trial: 14967189
Drug: Nicotine-patch therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-patch therapy for 8 weeks
Trial: 14967189
Drug: Nicotine-patch therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-patch therapy
Trial: 9272748
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide treatment
Trial: 3066967
Drug: Ryodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryodipine (30 mg single dose)
Trial: 3066967
Drug: Ryodipine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryodipine (150 mg/day for a short period)
Trial: 3066967
Drug: Ryodipine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryodipine (150 mg/day)
Trial: 3066967
Drug: Ryodipine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryodipine (250 mg/day)
Trial: 31209710
Drug: Ultrasound-guided local
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided local insulin injection
Trial: 31209710
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 40 mg methylprednisolone acetate
Trial: 31209710
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection followed by insulin injection twice after 2 and 4 weeks
Trial: 12929098
Drug: Rotational atherectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotational atherectomy (RA) and adjunctive balloon angioplasty (PTCA)
Trial: 8471818
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day n‐3 fatty acids
Trial: 8471818
Drug: 4.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g/day n‐3 fatty acids
Trial: 8471818
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acids treatment
Trial: 3899152
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) 0.5 mg i.v.
Trial: 17080448
Drug: Integrative cognitive-affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive-affective therapy
Trial: 17080448
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment approaches